Sofosbuvir Off-label Treatment of Yellow Fever Patients During an Outbreak in Brazil, 2018: A Cohort Study

被引：3

作者：

Rezende, Izabela M. ^{[1
,2
,9
]}

Mendonca, Diogo Correa ^{[3
]}

Costa, Thais Alkifeles ^{[2
]}

de Oliveria, Gabriela Fernanda Garcia ^{[2
]}

Arruda, Matheus Soares ^{[2
]}

Goncalves, Andreza Parreiras ^{[4
]}

Alves, Pedro Augusto ^{[4
]}

Calzavara-Silva, Carlos Eduardo ^{[5
]}

Martins-Filho, Olindo A. ^{[6
]}

Teixeira-Carvalho, Andrea ^{[6
]}

Bonjardim, Claudio Antonio ^{[2
]}

Monath, Thomas P. ^{[7
]}

LaBeaud, A. Desiree ^{[1
]}

Drumond, Betania P. ^{[2
]}

Pascoal-Xavier, Marcelo Antonio

Pereira, Leonardo S. ^{[8
,10
]}

Ramalho, Dario Brock ^{[8
,11
]}

机构：

[1] Stanford Univ, Sch Med, Dept Pediat, Div Infect Dis, Stanford, CA USA

[2] Univ Fed Minas Gerais, Biol Sci Inst, Microbiol Dept, Lab Viruses, 6627 Antonio Carlos Ave Pampulha, BR-31270901 Belo Horizonte, MG, Brazil

[3] Univ Glasgow, Ctr Virus Res, MRC, Glasgow, Scotland

[4] Oswaldo Cruz Fdn Fiocruz, Rene Rachou Inst, Immunol Viral Dis, Belo Horizonte, MG, Brazil

[5] Oswaldo Cruz Fdn Fiocruz, Rene Rachou Inst, Cellular & Mol Immunol, Belo Horizonte, MG, Brazil

[6] Oswaldo Cruz Fdn Fiocruz, Rene Rachou Inst, Integrated Grp Biomarkers Res, Belo Horizonte, MG, Brazil

[7] Crozet Biopharm LLC, Lexington, MA USA

[8] Eduardo Menezes Hosp, Belo Horizonte, MG, Brazil

[9] Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Stanford Med Pandem Preparedness Hub, 240 Pasteur Dr Biomed Innovat Bldg BMI,3rd floor,R, Stanford, CA 94305 USA

[10] Bendigo Hlth, Bendigo, Vic, Australia

[11] Pan Amer Hlth Org, Brasilia, DF, Brazil

来源：

OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 06期

基金：

美国国家卫生研究院;

关键词：

antiviral; genomic viral load; sofosbuvir; yellow fever; yellow fever virus;

D O I：

10.1093/ofid/ofae312

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We enrolled 21 patients with laboratory-confirmed yellow fever (YF), hospitalized at Eduardo de Menezes Hospital, Brazil, to be treated with sofosbuvir, a drug approved for hepatitis C. Given the absence of specific YF antiviral treatments, the off-label nonrandomized sofosbuvir treatment aimed to address high disease severity and the risk of fatal outcomes. Patients received a daily dose of 400 mg sofosbuvir from 4 to 10 days post-symptom onset. YF viral load (VL) comparisons were made between treated and nontreated patients who either survived or died. The genomic VL for the treated group steadily decreased after day 7 post-symptom onset, suggesting that sofosbuvir might reduce YF VL. This study underscores the urgent need for YF antiviral therapies, advocating for randomized clinical trials to further explore sofosbuvir's role in YF treatment.

引用

页数：4

共 50 条

[21] Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients
Akar, Servet
Cetin, Pinar
Kalyoncu, Umut
Karadag, Omer
Sari, Ismail
Cinar, Muhammed
Yilmaz, Sedat
Onat, Ahmet Mesut
Kisacik, Bunyamin
Erden, Abdulsamet
Balkarli, Ayse
Kucuksahin, Orhan
Oner, Sibel Yilmaz
Senel, Soner
Tufan, Abdurrahman
Direskeneli, Haner
Oksuz, Ferhat
Pehlivan, Yavuz
Bayindir, Ozun
Keser, Gokhan
Aksu, Kenan
Omma, Ahmet
Kasifoglu, Timucin
Unal, Ali Ugur
Yildiz, Fatih
Balci, Mehmet Ali
Yavuz, Sule
Erten, Sukran
Ozgen, Metin
Sayarlioglu, Mehmet
Dogru, Atalay
Yildirim, Gozde
Oner, Fatma Alibaz
Tezcan, Mehmet Engin
Pamuk, Omer Nuri
Onen, Fatos
ARTHRITIS CARE & RESEARCH, 2018, 70 (07) : 1090 - 1094
[22] Yellow Fever Vaccine in 435 Egg Allergic Children During 2018-2019 Yellow Fever Epidemic in Brazil
Rocha, Wilson
Lopes, Fernanda
Oliviera, Livia
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB103 - AB103
[23] Off-label use and harmful potential of drugs in a NICU in Brazil: A descriptive study
Alcidésio Sales de Souza
Djanilson Barbosa dos Santos
Luís Carlos Rey
Marina Garruti Medeiros
Marta Gonçalves Vieira
Helena Lutéscia Luna Coelho
BMC Pediatrics, 16
[24] Off-label use and harmful potential of drugs in a NICU in Brazil: A descriptive study
de Souza, Alcidesio Sales, Jr.
dos Santos, Djanilson Barbosa
Rey, Luis Carlos
Medeiros, Marina Garruti
Vieira, Marta Goncalves
Luna Coelho, Helena Lutescia
BMC PEDIATRICS, 2016, 16
[25] Risk factors associated with in-hospital mortality during yellow fever outbreak in Brazil
Mcclure, Max
de Rezende, Izabela Mauricio
Pereira, Leonardo Soares
Dutra, Maria Rita Teixeira
Fradico, Jordana Rodrigues Barbosa
Macedo, Rodrigo
Marcal, Marcelle Cardoso
Boa, Livia Soares Coelho Fonte
Bragato, Alexandre Mauricio Castro
Faria, Flavio Augusto de Almeida
Pamplona, Livia
Said, Rodrigo Fabiano do Carmo
Calzavara-Silva, Carlos Eduardo
Ramalho, Dario Brock
Magalhaes, Cintia Lopes de Brito
Alves, Pedro Augusto
Gama, Thaysa Drummond Palmeira
Cota, Glaucia Fernandes
Monath, Thomas P.
Martins-Filho, Olindo Assis
Pascoal-Xavier, Marcelo Antonio
Teixeira-Carvalho, Andrea
Drumond, Betania Paiva
Labeaud, A. Desiree
Yellow Fever Collaborative Grp
FRONTIERS IN MEDICINE, 2025, 12
[26] RufinamideAggravation of atonic seizure during off-label treatment: case report
Reactions Weekly, 2016, 1611 (1) : 151 - 151
[27] AzithromycinElevated transaminase levels during off-label treatment: case report
Reactions Weekly, 2021, 1855 (1) : 77 - 77
[28] Administration of label and off-label drugs by the subcutaneous route in palliative care: an observational cohort study
Jensen, Jesper Jorgen
Sjogren, Per
BMJ SUPPORTIVE & PALLIATIVE CARE, 2022, 12 (E6) : E723 - E729
[29] BevacizumabVarious toxicities during off-label treatment: 2 case reports
Reactions Weekly, 2019, 1772 (1) : 76 - 76
[30] Azithromycin/hydroxychloroquineQTc prolongation during off-label treatment: case report
Reactions Weekly, 2021, 1845 (1) : 95 - 95

← 1 2 3 4 5 →